146 results about "Situ breast cancer" patented technology

The invention relates to a novel intelligent bra for early detection of breast cancer. The intelligent bra carries ultra-high sensitive computer micro-processing chips, which include temperature sensor, blood flow sensors, oxyhemoglobin quantity sensors and the like for all-round acquisition of breast tissue temperature, blood flow and the hemoglobin amount. The device saves periodically collected data in a computer through a wireless transmission system, and automatically analyzes and alarms whether carcinogenesis possibility exists in breasts.

Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.

The invention discloses lncRNA and application thereof as a detection marker or a prognosis recurrence marker for breast cancer combined with lung cancer. The lncRNA is at least one of the following nucleic acid molecules: (1) nucleic acid molecules with cDNA sequences as shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3; and (2) nucleic acid molecules with 90% and higher homology with the nucleic acid molecules with the cDNA sequences as shown in the SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.3. According to the lncRNA and application thereof, a group of lncRNAs are screened out as the molecular markers for the breast cancer combined with lung cancer, associated primers are optimized for preparing primer probe chips, and the lncRNA has the advantages of low detection cost, high sensitivity and the like; and the lncRNA and application thereof take the breast cancer combined with lung cancer, such combined cancer, as an example, and take the lead in filling up the blank in research of the combined biological marker lncRNA in China. The lncRNA and application thereof adopt a group of lncRNAs as associated biological markers for combined cancer, and can effectively improve the clinical diagnosis and prognosis evaluation of the combined cancer for instructing clinical treatment.

A method of treating a cancerous region in a breast of a patient comprising (i) imaging the breast in a three-dimensional coordinate system, (ii) stereotactically determining the location of the cancerous region in the breast, (iii) optionally determining the volume of the entire cancerous region to be treated, and (iv) while maintaining the breast in a three-dimensional coordinate system that is identical to or corresponds with the three-dimensional coordinate system used in (i), noninvasively exposing the cancerous region of the breast of the patient to a cancer-treatment effective dose of radiation; and equipment for use in such a method.

Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.

Methods for treating breast cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described. The compound can be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatment.

Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy; and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and / or penetrate a type of cell; and a sulfonated corrole molecule bound to the polypeptide sequence.

This disclosure describes APOBEC3B as a biomarker for certain cancers such as, for example, breast cancer. This disclosure therefore describes methods for detecting APOBEC3B in a biological sample. The methods generally include measuring expression of APOBEC3B in a biological sample obtained from a patient and identifying the patient as having or at risk for having cancer if the measured expression of APOBEC3B is greater than a predetermined reference level of expression. This disclosure also describes isolated polynucleotides that may be used as reagents in methods for detecting and / or measuring APOBEC3B expression.

The present invention provides use of protein kinase C-zeta (PKC-ζ) as a diagnostic biomarker for breast cancer tumorigenesis. Also provided are uses of PKC-zeta inhibitors for inhibiting breast cancer tumorigenesis and for treatment of breast cancer.